Market Place
Sourcing Support
Chugai obtains Japanese approval for FoundationOne Liquid CDx Genomic Profile
27 May 2023 //
PHARMABIZ
Novartis announces MET inhibitor Tabrecta™ approved in Japan METex14
29 Jun 2020 //
PRESS RELEASE
Chugai gets Japanese approval for expanded use of FoundationOne CDx Genomic
29 May 2020 //
PHARMABIZ
Novartis leans into digital for mid-pandemic lung cancer launch
11 May 2020 //
FIERCEPHARMA
FDA okays Tabrecta, adds indication for Farxiga
09 May 2020 //
RAPS
FDA approval for Tabrecta in metastatic non-small cell lung cancer with METex14
08 May 2020 //
PHARMAFILE
FDA approval for Tabrecta in metastatic non-small cell lung cancer with METex14
07 May 2020 //
PHARMAFILE
Novartis lands capmatinib approval, giving them a second blockbuster from Incyte
07 May 2020 //
ENDPTS
Novartis beats out Merck KGaA with lung cancer drug Tabrecta
07 May 2020 //
FIERCE PHARMA
Incyte Announces FDA Approval of Tabrecta™ (capmatinib) for the Treatment
06 May 2020 //
BUSINESSWIRE
Foundation Medicine Receives FDA Approval for FoundationOne®CDx
06 May 2020 //
BUSINESSWIRE
Novartis announces FDA approval of MET Tabrecta™ for metastatic NSCLC
06 May 2020 //
PRNEWSWIRE
Novartis` capmatinib tackles lung cancer in the brain: study
27 Apr 2020 //
FIERCE PHARMA
Roche`s Tecentriq, on top of targeted drugs, stalls melanoma
26 Apr 2020 //
FIERCE PHARMA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.